NCT03307512View on ClinicalTrials.gov

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

July 30, 2019

Study Completion Date

August 30, 2019

Conditions
Safety and Tolerability
Interventions
DRUG

inhaled human insulin

Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation

DRUG

Insulin Lispro (Humalog U-100)

Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection

Trial Locations (1)

90630

WCCT, Cypress

Sponsors

Collaborators (1)

WCCT Global
All Listed Sponsors
collaborator

WCCT Global

INDUSTRY

lead

Dance Biopharm Inc.

INDUSTRY

NCT03307512 - PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD | Biotech Hunter | Biotech Hunter